Medite Cancer Diagnostics Inc · OTC:MDIT
Medite Cancer Diagnostics — Investor Presentation (May 2015)
9 slides from Medite Cancer Diagnostics's investor presentation, May 27, 2015
Slide 1: Building a Global Force in Cancer Diagnostics
The World Is Being Overrun By A “Tidal Wave Of Cancer” - WHO Says (Source: Sarah Boseley, The Guardian, Feb. 4th 2014) Building a Global Force in Cancer World Cancer Report 2014 (WHO) Increasing global burden of cancer Diagnostics In 2012, the worldwide burden of cancer rose to an estimated 14 milli
Slide 2: Forward Looking Statements
This presentation contains “forward looking statements” as defined by the Private Securities Litigation Reform Act of 1995 and includes statements as to expectations, forecasts and future financial performance. These statements that are not historical facts are forward looking. Readers are directed
Slide 3: About MEDITE (MDIT): Now and the Future
Now: Latest Established 1978 in Germany, the Level of current management team acquired Automation - MEDITE in 2006; merged with the last step Cytocore in 2014, and is currently, before fully headquartered in Orlando, FL USA Automation About Manufacturer of Laboratory process MEDITE automation an
Slide 4: Worldwide Pathology Market Overview
Worldwide Pathology Market Overview 4
Slide 5: New Cytology Power
Cell Processing Systems for Liquid-Based-Cytology Select Medite Products Targeting and Substitutes Hologic and Becton-Dickinson Systems Lower Price compared with same or higher quality New Cytology High Volume Cervical Cancer Screening Market Power Other Applications like Bladder and Lung
Slide 6: Build and Growth Strategy
China: New programs for 2015 and 2016 (1.4 billion population) Histology and Cytology • All Medite Instruments are now Chinese FDA approved • Chinese distribution partner UNIC Medical spent already 800,000 USD on CFDA approval fees • In-house purchase orders from China on histology equipment in Q1/2
Slide 7: MEDITE Solution 1: New Histology Standardization program
New CLOUD-based technology combined with MEDITE histology equipment and UNIC digital slide scanners MEDITE Solution 1 New Histology Standardization program • MEDITE histology instruments will participating in the histology program in China • Forecasted 2.3 Mio USD in histology instruments sales in 2
Slide 8: MEDITE Solution 2: New Cytology Standardization program
• It's estimated that up to 80 percent of women will get an HPV infection at some point in their lives • Targeting Asia and Middle East countries first with this standardization program • Potential market size for Asia and Middle East is about 320 million annual tests for women between 35~55 years o
Slide 9: New Products Innovations, Developments and New Technologies
Breast Aspirant-Cell Collector 25% of all female cancer cases are breast cancer Non-invasive breast cancer risk assesment procedure targeting women between 20-45 $75 affordable retail charge, low console cost Plan to place in Doctor‘s offices and clinics free of charge; razor blade economics
Medite Cancer Diagnostics — Investor Presentation (May 2015) on 6ix